oral
corticosteroid
cornerston
acut
asthma
manag
emerg
depart
recent
evid
rais
doubt
efficaci
treatment
preschoolag
children
viralinduc
wheez
smoke
adult
aim
studi
document
magnitud
respons
oral
corticosteroid
children
present
emerg
depart
moder
sever
asthma
quantifi
potenti
determin
respons
corticosteroid
explor
role
gene
polymorph
associ
respons
corticosteroid
design
prospect
cohort
studi
children
age
year
meet
strict
definit
asthma
present
clinic
score
valid
pediatr
respiratori
assess
measur
pram
children
receiv
standard
severityspecif
treatment
prednisoneprednisolon
cointervent
salbutamol
withwithout
ipratropium
bromid
determin
name
viral
aetiolog
environment
tobacco
smoke
singl
nucleotid
polymorph
object
document
primari
efficaci
endpoint
hospit
admiss
within
hour
secondari
endpoint
includ
measur
asthma
sever
time
recoveri
within
day
index
visit
studi
power
detect
risk
differ
associ
determin
baselin
risk
ethic
approv
obtain
particip
institut
impair
respons
system
steroid
certain
subgroup
challeng
current
standard
practic
call
immedi
search
better
approach
potenti
hostenviron
interact
broaden
understand
respiratori
ill
asthma
one
frequent
paediatr
diagnos
requir
hospit
admiss
burden
ill
much
higher
preschoolag
children
account
ed
visit
three
time
hospit
admiss
rate
older
children
adolesc
difficulti
measur
asthma
sever
young
children
result
dearth
compar
therapeut
evid
preschool
older
children
treatment
acut
asthma
nation
intern
guidelin
manag
acut
asthma
recommend
inhal
patient
system
usual
oral
corticosteroid
moder
sever
asthma
repeat
dose
inhal
agonist
anticholinerg
sever
case
latter
two
recommend
independ
reduc
admiss
rate
studi
predominantli
schoolag
children
sever
featur
must
note
first
recommend
severityspecif
patient
mild
asthma
appear
benefit
oral
corticosteroid
second
concept
golden
first
hour
treatment
support
earli
aggress
asthma
manag
risk
admiss
reduc
oral
corticosteroid
administ
hour
prior
decis
admit
third
treatment
administ
ed
oral
corticosteroid
far
effect
prevent
admiss
fourth
equal
effect
substitut
oral
corticosteroid
promis
contend
highdos
inhal
steroid
intraven
antileukotrien
magnesium
sulfat
shown
inferior
oral
corticosteroid
use
addon
therapi
fifth
system
corticosteroid
inexpens
gener
drug
short
treatment
oral
corticosteroid
gener
devoid
signific
side
effect
though
rare
case
fatal
dissemin
varicella
report
sixth
recommend
rel
similar
young
children
older
children
adult
evid
former
weaker
due
underrepresent
preschoolag
children
relev
trial
oral
corticosteroid
cornerston
manag
acut
moder
sever
asthma
sever
report
recent
shaken
belief
equal
effect
patient
asthma
show
children
viralinduc
wheez
smoke
adult
corticosteroidresist
inde
larg
placebocontrol
random
control
trial
children
age
month
mildtomoder
viralinduc
wheez
oral
corticosteroid
superior
placebo
reduc
length
stay
hospit
improv
pram
clinic
score
despit
adequ
studi
power
critic
suggest
children
diseas
may
asthma
document
patient
rather
north
american
definit
bronchiol
patient
mild
asthma
may
need
corticosteroid
prolong
stay
hospit
seem
support
sever
dose
instead
mgkg
may
insuffici
yet
studi
elicit
major
discomfort
regard
acut
asthma
manag
young
children
anoth
adequ
power
landmark
trial
treatment
prednison
show
mark
blunt
respons
adult
smoker
improv
forc
expiratori
volum
second
ml
ci
neversmok
compar
chang
ml
current
smoker
question
remain
whether
smoke
adolesc
children
environment
tobacco
smoke
et
respond
well
expos
none
aforement
find
replic
thu
prompt
us
review
potenti
determin
respons
children
bronchiol
respond
oral
corticosteroid
although
recent
trial
demonstr
signific
respons
associ
nebulis
epinephrin
thu
critic
distinguish
asthma
bronchiol
young
children
bronchiol
clinic
defin
north
america
first
wheez
ill
child
month
respiratori
syncyti
viru
rsv
frequent
pathogen
asthma
defin
airway
obstruct
cough
dyspnoea
wheez
hyperreact
revers
bronchodil
corticosteroid
begin
earli
life
children
adult
meet
criteria
diagnos
first
episod
gener
three
wheez
episod
requir
children
month
reduc
risk
misclassif
bronchiol
heterogen
group
children
bronchiol
asthma
may
explain
poor
respons
oral
corticosteroid
studi
includ
infant
toddler
thu
oper
definit
asthma
clinic
applic
children
age
year
need
reason
exclud
bronchiol
urti
usual
viral
origin
frequent
trigger
asthma
exacerb
children
rsv
parainfluenza
viru
rhinoviru
frequent
implic
children
two
year
old
picornaviru
coronaviru
influenza
usual
associ
asthma
older
children
incid
viralinduc
asthma
peak
septemb
continu
throughout
fall
winter
adult
acut
asthma
viral
infect
associ
longer
hospit
admiss
increas
sputum
neutrophil
suggest
predominantli
neutrophil
airway
inflamm
studi
children
age
month
infect
rhinoviru
show
fewer
relaps
treat
oral
prednison
compar
placebo
suggest
rhinoviru
impair
respons
steroid
anoth
placebocontrol
trial
young
children
wheez
prednisolon
significantli
decreas
overal
time
discharg
howev
reduc
half
length
stay
children
infect
picornaviru
fourfold
children
enteroviru
suggest
respons
may
organismdepend
clearli
oral
corticosteroid
may
f
r
p
e
e
r
r
e
v
e
w
n
l
effect
patient
viral
infect
without
perhap
due
neutrophil
airway
inflamm
condit
associ
poor
respons
corticosteroid
moreov
respons
may
organismspecif
hypothesi
requir
care
document
aetiolog
addit
aforement
trial
demonstr
respons
oral
corticosteroid
asthmat
adult
smoker
blunt
respons
inhal
corticosteroid
also
document
adult
smoker
two
random
control
trial
mechan
behind
lack
respons
known
one
certainli
point
smoke
direct
toxic
proinflammatori
action
interfer
transcript
gene
associ
corticosteroid
respons
inde
smoke
frequent
associ
airway
neutrophilia
paediatr
exposur
tobacco
smoke
associ
higher
incid
urti
preval
asthma
greater
sever
exacerb
howev
impact
therapeut
respons
document
children
asthma
trial
examin
fail
report
subgroup
analys
et
exposur
activ
smoke
heavier
et
exposur
preschool
spend
time
home
schoolag
children
may
explain
poorer
respons
young
children
object
document
smoke
would
also
import
possibl
even
high
school
mani
alreadi
smoke
particular
concern
whether
blunt
respons
oral
corticosteroid
would
found
children
expos
tobacco
smoke
adolesc
short
histori
activ
smoke
asthmat
children
expos
et
teenag
activ
smoke
assess
appear
critic
sever
report
highlight
need
object
measur
nicotin
exposur
parent
underreport
child
exposur
environment
tobacco
smoke
cotinin
nicotin
metabolit
halflif
hour
wide
accept
indic
recent
tobacco
use
serum
cotinin
requir
blood
sampl
major
deterr
studi
particip
paediatr
good
correl
exist
serum
either
salivari
urin
cotinin
measur
ratio
cotinin
level
saliva
urin
passiv
exposur
may
lead
saliva
level
ngml
urin
level
ngml
howev
urin
sampl
young
children
may
occur
sever
hour
complex
obtain
children
yet
toilettrain
saliva
cotinin
measur
quantit
enzym
immunoassay
kit
wellvalid
noninvas
solut
offer
requir
precis
minim
volum
detect
level
ngml
number
factor
could
possibl
modul
respons
oral
corticosteroid
includ
among
other
gender
race
perceiv
asthma
phenotyp
deriv
age
common
asthma
trigger
interim
symptom
inhal
corticosteroid
allergen
alleg
trigger
environment
trigger
document
clinic
questionnair
two
promis
mechanist
pathway
may
explain
variat
magnitud
respons
observ
clinic
effect
name
gene
polymorph
may
reveal
potenti
geneenviron
interact
type
airway
inflamm
increas
evid
inherit
gene
determinist
genotyp
rather
genotyp
encod
potenti
rang
phenotyp
develop
respons
varieti
environ
consequ
minor
polymorph
individu
gene
modul
respons
corticosteroid
may
predispos
peopl
environmentallyinduc
problem
smokeor
viralinduc
asthma
two
major
group
gene
interest
affect
suscept
asthma
directli
interf
respons
corticosteroid
code
major
compon
pathway
involv
corticosteroid
action
tabl
first
group
select
polymorph
gene
divid
code
xenobiot
metabol
enzym
code
mediat
inflamm
immun
specif
one
demonstr
affect
lung
function
diseas
sever
interact
exposur
et
select
polymorph
affect
gene
function
toprank
snp
number
associ
studi
polymorph
found
correl
diseas
sever
polymorph
play
role
develop
persist
asthma
phenotyp
childhood
polymorph
link
pathogenesi
asthma
lung
function
smoker
gene
confer
suscept
earlyonset
asthma
particularli
interact
earli
life
exposur
et
involv
metabol
polycycl
aromat
hydrocarbon
deriv
reactiv
oxygen
speci
null
genotyp
associ
increas
risk
asthma
rapid
declin
lung
function
among
smoker
receptor
gene
found
contribut
occurr
wheez
among
children
expos
tobacco
smoke
utero
earli
childhood
relat
agonist
respons
among
gene
affect
corticosteroid
inflammatori
pathway
select
gene
shown
correl
respons
corticosteroid
patient
asthma
find
replic
sever
cohort
select
polymorph
gene
name
posit
correspond
refer
summar
tabl
genotyp
essenti
link
observ
corticosteroid
respons
genotyp
evalu
potenti
hostenviron
interact
induc
sputum
valid
reproduc
noninvas
method
assess
magnitud
pattern
airway
inflamm
adult
children
sputum
cell
count
differenti
ie
eosinophil
neutrophil
determin
inflammatori
phenotyp
analysi
supernat
eosinophil
cation
protein
ecp
myeloperoxidas
provid
measur
cellular
activ
sputum
eosinophil
ecp
increas
exposur
allergen
decreas
corticosteroid
treatment
higher
proport
neutrophil
associ
smoke
viral
infect
noneosinophil
inflammatori
phenotyp
adult
associ
poor
respons
corticosteroid
marker
phenotyp
includ
increas
proport
neutrophil
myeloperoxidas
easili
quantifi
contrari
adult
find
criteria
three
distinct
inflammatori
cell
pattern
report
paediatr
exacerb
noneosinophil
eosinophil
eosinophil
eosinophil
combin
eosinophilicneutrophil
eosinophil
neutrophil
paucigranular
inflamm
describ
acut
paediatr
athma
combin
eosinophilicneutrophil
exacerb
show
mast
cell
higher
sputum
ecp
level
eosinophil
exacerb
increas
evid
eosinophil
asthma
respons
corticosteroid
noneosinophil
asthma
promis
mechanist
pathway
explor
expir
nitric
oxid
eno
increasingli
recogn
noninvas
marker
airway
inflamm
particularli
atop
asthma
correl
strongli
percentag
airway
eosinophil
ecp
children
asthma
although
understand
link
airway
inflamm
remain
incomplet
airway
epitheli
cell
activ
inflammatori
cytokin
produc
increas
amount
eno
due
express
induc
synthas
ino
expir
elev
untreat
asthma
improv
asthma
therapi
correl
marker
eosinophil
inflamm
includ
sputum
eosinophil
thu
eno
appear
reflect
magnitud
eosinophil
airway
inflammatori
may
serv
promis
biomark
eosinophil
inflamm
children
young
unabl
cooper
induc
sputum
sampl
measur
preschoolag
use
offlin
techniqu
older
children
use
commerci
avail
instrument
could
serv
biomark
subsequ
respons
corticosteroid
inde
type
airway
inflamm
modul
respons
need
hospit
admiss
power
marker
therapi
failur
like
alter
physician
practic
influenc
decis
maker
hospit
cost
alon
account
total
asthma
cost
although
subject
practic
variat
physician
decis
admit
usual
base
unsatisfactori
respons
bronchodil
system
corticosteroid
ed
indic
sever
asthma
poor
respons
corticosteroid
admiss
may
affect
reason
parent
anxieti
distanc
fatigu
cours
avail
ed
hospit
bed
ad
cutoff
length
ed
stay
patient
consid
admit
limit
impact
extern
factor
bed
avail
may
vari
wide
within
institut
moreov
incorpor
return
visit
result
admiss
provid
addit
measur
failur
ed
treatment
ad
measur
decis
appropri
time
meet
sever
criteria
discharg
pram
length
activ
treatment
two
addit
measur
interest
less
influenc
factor
sever
accur
object
assess
sever
airway
obstruct
clearli
biggest
challeng
acut
paediatr
asthma
research
standard
lung
function
test
spirometri
requir
forc
expiratori
manoeuvr
extrem
difficult
unreli
preschoolag
children
poor
coordin
obtain
acut
ill
schoolag
children
ill
sever
andor
poor
familiar
techniqu
threequart
asthmat
children
perform
standard
lung
function
test
ed
set
contrast
respiratori
resist
forc
oscil
effortindepend
measur
obtain
untrain
acut
ill
children
age
year
other
demonstr
reproduc
sensit
chang
respiratori
resist
establish
refer
valu
canadian
children
thu
measur
respiratori
resist
rr
serv
precis
reliabl
index
sever
respons
acut
ill
children
although
still
miss
young
uncoop
preschool
serv
main
outcom
clinic
score
appear
reason
altern
lung
function
test
use
children
age
although
mani
clinic
score
design
two
valid
use
preschool
schoolag
children
pram
score
develop
valid
concurr
measur
lung
function
children
age
year
subsequ
valid
children
age
year
discrimin
respons
tool
chang
score
indic
clinic
import
interrat
reliabl
consist
pram
rate
five
weight
item
oxygen
satur
suprastern
retract
scalen
muscl
contract
air
entri
wheez
use
landmark
clinic
trial
among
children
discharg
home
time
complet
recoveri
vari
wide
individu
although
symptom
score
frequent
use
clinic
trial
four
specif
develop
use
children
asthma
flareup
diari
young
children
formerli
pediatr
asthma
diari
one
valid
detect
daytoday
chang
function
statu
preschoolag
children
follow
acut
care
visit
highli
sensit
detect
group
differ
intens
durat
symptom
random
control
trial
howev
perform
schoolag
children
explor
anoth
diari
valid
detect
chang
schoolag
children
context
acut
ill
children
use
agonist
addit
marker
durat
intens
symptom
greater
use
rescu
reliev
expect
occur
children
symptom
final
impact
diseas
qualiti
life
patient
caregiv
recogn
sensit
uniqu
marker
burden
diseas
patient
famili
sever
wellvalid
asthmaspecif
qualiti
life
instrument
avail
adult
schoolag
children
stabl
asthma
knowledg
one
instrument
entitl
effect
child
asthma
flareup
parent
avail
measur
burden
diseas
parent
preschoolag
children
follow
asthma
exacerb
develop
instrument
use
kirshner
guaytt
approach
develop
health
instrument
children
present
moder
sever
asthma
ed
main
object
identifi
quantifi
clinic
avail
factor
eg
age
specif
viral
trigger
et
associ
hospit
admiss
marker
clinic
respons
oral
corticosteroid
preschool
schoolag
children
present
ed
moder
sever
asthma
examin
associ
specif
genet
polymorph
includ
potenti
hostenviron
interact
marker
respons
determin
whether
type
airway
inflamm
ie
eosinophil
eno
associ
magnitud
respons
corticosteroid
host
episod
characterist
associ
specif
type
inflamm
studi
design
multicentr
prospect
cohort
studi
standard
intervent
involv
children
age
year
old
present
acut
asthma
one
five
particip
canadian
paediatr
emerg
depart
studi
includ
nest
cohort
studi
children
present
patient
exclud
present
anoth
chronic
respiratori
condit
bronchopulmonari
dysplasia
cystic
fibrosi
reason
suspicion
bronchiol
foreign
bodi
aspir
prior
histori
hypersensit
salbutamol
ipratropium
bromid
oral
prednisolon
rel
absolut
contraind
receiv
oral
corticosteroid
recent
exposur
varicella
live
vaccin
suscept
child
confirm
suspect
pregnanc
statu
inclus
exclus
criteria
may
becom
evid
ed
stay
ie
pneumonia
central
adjud
committe
compris
paediatrician
physician
respirologistradiologist
review
elig
criteria
children
enrol
appear
inelig
due
failur
meet
one
inclus
exclus
criteria
receiv
toler
oral
corticosteroid
recommend
protocol
main
trigger
identifi
children
ed
physician
low
degre
confid
child
asthma
hesh
bronchiol
suspicion
hesh
retain
corticosteroid
case
relev
crf
relev
anonym
laboratori
test
ie
imag
microbiolog
virolog
haematolog
relev
anonym
medic
chart
section
review
adjud
committe
adjud
committe
central
although
rule
possibl
creat
local
committe
site
depend
volum
case
review
case
site
would
ad
covari
analysi
disagr
resolv
consensu
assist
third
observ
proport
exclud
children
assum
around
monitor
report
per
evidencebas
paediatr
nation
intern
guidelin
children
treat
accord
standard
severityspecif
protocol
tabl
children
receiv
mgkg
max
mg
oral
prednisolon
prednison
within
minut
triag
along
inhal
salbutamol
without
inhal
ipratropium
bromid
per
sever
strata
discharg
medic
includ
cours
oral
prednisolon
dose
mgkgday
inhal
agonist
need
cointervent
addon
therapi
magnesium
sulphat
ed
inhal
corticosteroid
discharg
permit
record
comorbid
eg
pneumonia
sinus
allerg
rhiniti
etc
advers
health
event
document
primari
outcom
serv
proxi
suboptim
respons
hospit
admiss
defin
hospit
admiss
asthma
primari
secondari
diagnosi
primari
complic
comorbid
asthma
ed
stay
asthma
activ
treatment
hour
intak
oral
corticosteroid
time
constraint
includ
account
extran
factor
affect
admiss
variat
bed
avail
child
remain
treatment
site
secondari
measur
effect
ed
includ
meet
sever
criteria
admiss
pram
score
within
hour
corticosteroid
administr
account
reason
hospit
admiss
ii
pram
profil
ed
measur
hourli
baselin
everi
hour
disposit
hr
intak
oral
corticosteroid
whichev
occur
first
report
area
curv
iii
time
pram
meet
criteria
discharg
iv
length
activ
treatment
defin
durat
first
last
salbutamol
inhal
final
allow
object
precis
quantif
respons
nest
cohort
chu
stejustin
v
chang
respiratori
resist
baselin
disposit
document
masterscreen
impuls
oscillometri
cardin
health
canada
montreal
canada
use
previous
describ
standard
techniqu
cooper
children
age
year
vi
chang
expir
nitric
oxid
baselin
disposit
document
chemiluminesc
nitric
oxid
analys
cooper
children
age
year
vii
failur
ed
treatment
defin
meet
hospit
admiss
criteria
defin
primari
outcom
discharg
hospit
admiss
asthma
primari
secondari
diagnosi
within
hr
discharg
return
visit
within
hr
asthma
primari
secondari
diagnosi
activ
ed
stay
hour
secondari
measur
resolut
exacerb
measur
discharg
document
next
day
patient
viii
unschedul
visit
asthma
report
parent
confirm
sociodemograph
variabl
basic
characterist
document
includ
age
gender
neighbourhood
financi
incom
deriv
postal
code
parent
separ
medic
insur
privat
public
ethnic
report
parent
classifi
per
latest
canadian
censu
questionnair
children
asthma
phenotyp
document
per
latest
intern
recommend
ie
viralinduc
exerciseinduc
allergeninduc
multipletrigg
prior
morbid
admiss
ed
visit
rescu
oral
corticosteroid
asthma
control
use
asthma
quiz
kidz
report
use
daili
control
medic
environment
factor
eg
dust
anim
pollen
perceiv
trigger
exacerb
document
prior
allergi
test
result
serum
ige
specif
obtain
permiss
well
pollen
count
area
acknowledg
virus
major
trigger
children
test
respiratori
virus
children
nasopharyng
aspir
npa
nasopharyng
swab
flock
swab
copan
diagnost
ca
perform
aspir
swab
put
ml
viral
transport
media
utm
copan
diagnost
ca
split
half
site
first
half
test
use
routin
method
site
clinic
requir
half
frozen
molecular
diagnosi
frozen
sampl
process
use
valid
autom
microarray
detect
test
common
respiratori
virus
includ
novel
influenza
passiv
exposur
tobacco
smoke
quantifi
questionnair
specif
enquir
current
amount
smoke
household
member
cumul
smoke
exposur
packyear
sinc
birth
utero
exposur
use
valid
question
activ
smoke
assess
ask
schoolag
children
age
year
older
alon
smoke
past
day
use
standard
question
use
quebec
institut
statist
quantit
cotinin
quantit
enzym
immunoassay
kit
salimetr
pa
usa
perform
saliva
sampl
use
three
sorbett
wand
small
spong
accord
previous
describ
protocol
sever
factor
consid
includ
assum
trigger
absenc
valid
biomark
causal
relationship
exacerb
alleg
trigger
allerg
base
parent
report
physician
percept
prior
document
sensit
skin
test
specif
ige
pollen
particl
ozon
level
child
live
area
serv
infer
trigger
genet
profil
patient
dna
extract
saliva
expector
collect
sorbett
design
young
children
small
amount
ml
need
dna
analysi
amplif
pcr
key
polymorph
determin
high
throughput
genotyp
technolog
sequenom
platform
custom
snp
panel
f
r
p
e
e
r
r
e
v
e
w
n
l
measur
taken
corticosteroid
hour
disposit
whichev
occur
first
children
unabl
cooper
techniqu
eno
also
measur
use
singl
breath
manoeuvr
inert
balloon
offlin
techniqu
analys
chemiluminesc
analyz
induc
sputum
initi
salbutamol
inhal
children
age
year
ask
expector
spontan
unsuccess
receiv
nebulis
salin
solut
minut
lmin
oxygen
techniqu
success
rate
obtain
among
acut
ill
schoolag
asthmat
children
throughout
induct
lung
function
test
use
respiratori
resist
document
ensur
cough
effort
induc
bronchospasm
sputum
process
accord
standard
techniqu
within
hour
briefli
sputum
separ
saliva
dispers
use
dithiothreitol
dispers
suspens
centrifug
filter
cytospin
slide
prepar
site
train
medic
technologist
supernat
frozen
subsequ
quantif
inflammatori
mediat
differenti
cell
count
inflammatori
mediat
analys
independ
laboratori
blind
exposur
outcom
within
institut
potenti
elig
patient
age
year
identifi
upon
arriv
ed
per
standard
practic
particip
hospit
children
triag
score
pram
shortli
triag
first
inhal
salbutamol
sever
exacerb
ipratropium
bromid
administ
figur
use
inform
consent
parent
first
give
author
child
receiv
standard
severityspecif
treatment
chu
stejustin
lung
function
test
induc
sputum
cooper
children
parent
f
r
p
e
e
r
r
e
v
e
w
n
l
receiv
detail
explan
studi
offer
studi
particip
particip
receiv
treatment
measur
detail
figur
key
measur
obtain
prior
corticosteroid
standard
summari
statist
n
mean
standard
deviat
median
minimum
maximum
continu
variabl
n
proport
categor
variabl
comput
variabl
whole
cohort
institut
twosid
confid
interv
present
necessari
primari
endpoint
hospit
admiss
dichotom
outcom
bivari
multivari
logist
regress
model
use
examin
associ
potenti
determin
adjust
site
baselin
sever
relev
covari
interest
odd
ratio
estim
present
twosid
confid
interv
continu
outcom
area
curv
repeat
pram
measur
daili
asthma
flareup
diari
young
intens
agonist
use
symptom
score
discharg
analys
use
linear
regress
model
transform
variabl
perform
necessari
account
nonnorm
residu
regard
pharmacogenom
compar
frequenc
snp
patient
admit
vs
discharg
use
fisher
exact
test
examin
strength
associ
admiss
bivari
multivari
logist
regress
genotyp
consid
variabl
two
domin
recess
model
three
addit
model
categori
choic
model
determin
function
select
polymorph
previou
report
bonferroni
correct
use
adjust
multipl
test
adjust
independ
gene
investig
hostenviron
interact
examin
ad
genotyp
model
covari
interest
exampl
investig
genet
heterogen
accord
earlylif
exposur
environment
tobacco
smoke
introduc
marker
tobacco
smoke
exposur
statu
regard
examin
eosinophil
inflamm
marker
respons
area
curv
serial
pram
measur
time
pram
serv
outcom
linear
regress
use
examin
bivari
multivari
relationship
sputum
eosinophil
count
pattern
inflamm
eosinophil
noneosinophil
mix
baselin
eno
pram
profil
area
curv
standard
surviv
curv
explor
differ
time
meet
criteria
discharg
censor
hour
model
check
use
appropri
regress
diagnost
result
report
signific
p
sampl
size
estim
two
step
use
hospit
admiss
depend
variabl
multivari
logist
regress
model
pilot
data
extract
two
larg
recent
chart
audit
total
children
present
acut
asthma
ed
age
gender
baselin
pram
time
oral
corticosteroid
intak
admiss
document
two
recent
complet
trial
total
children
tobacco
exposur
also
ascertain
questionnair
focus
children
meet
current
elig
criteria
age
baselin
pram
corticosteroid
within
hour
arriv
base
literatur
assum
preval
viral
pathogen
vari
baselin
risk
admiss
recruit
initi
patient
observ
overal
risk
admiss
substanti
lower
substanti
reduc
effect
sampl
size
first
use
wald
test
use
preval
factor
risk
admiss
unexpos
calcul
sampl
size
requir
detect
risk
differ
rd
admiss
take
determin
turn
independ
variabl
bivari
logist
regress
use
confid
interv
estim
obtain
pilot
data
examin
impact
power
use
method
propos
hsieh
et
al
calcul
inflat
factor
adjust
total
sampl
size
base
observ
correl
key
determin
age
gender
tobacco
exposur
baselin
sever
observ
correl
determin
sever
pair
determin
neglig
phi
coeffici
need
inflat
sampl
size
alpha
sampl
children
power
detect
risk
differ
admiss
key
determin
target
risk
differ
consid
survey
research
pediatr
emerg
research
canada
perc
network
clinic
meaning
effect
size
would
support
practic
chang
document
lost
enrol
origin
estim
miss
key
sampl
viral
cotinin
target
recruit
sampl
obtain
effect
sampl
children
acknowledg
major
select
polymorph
minor
allel
frequenc
least
use
alpha
bonferroni
correct
polymorph
children
provid
power
detect
polymorph
admiss
final
expect
children
recruit
univers
health
centr
saintejustin
estim
children
would
cooper
eno
measur
induc
sputum
sampl
size
adequ
detect
correl
coeffici
low
respect
area
curv
pram
score
ed
power
twosid
studi
pose
littl
risk
particip
children
receiv
stateoftheart
asthma
manag
oral
corticosteroid
approach
associ
minim
side
effect
children
assess
potenti
contraind
corticosteroid
prior
enrol
use
inform
consent
parent
first
give
author
child
receiv
severityspecif
asthma
protocol
specif
centr
lung
function
test
induc
sputum
cooper
children
consent
full
studi
includ
sampl
cotinin
dna
virus
parent
sign
inform
consent
form
author
dna
analysi
specifi
research
purpos
well
futur
analys
includ
biobank
dna
anonym
fashion
provid
approv
institut
ethic
board
assent
obtain
children
age
collect
saliva
expector
spong
painless
well
toler
children
nasopharyng
aspir
swab
viral
diagnosi
commonli
use
procedur
ed
set
rapid
associ
littl
discomfort
perform
respiratori
resist
eno
noninvas
devoid
seriou
side
effect
sputum
induct
salin
salbutamol
pretreat
safe
procedur
acut
care
set
data
safeti
maxim
restrict
physic
access
comput
electron
protect
server
firewal
restrict
passwordprotect
access
daili
backup
storag
differ
locat
confidenti
also
part
standard
oper
procedur
uniqu
research
code
assign
patient
research
data
specimen
kept
lock
room
restrict
access
site
coordin
centr
site
analysi
protocol
consent
form
amend
subject
ethic
review
board
approv
institut
investig
adher
principl
declar
helsinki
seriou
advers
effect
promptli
report
studi
provid
need
answer
whether
oral
corticosteroid
less
effect
prevent
hospit
admiss
subgroup
children
clinic
avail
characterist
could
use
identifi
patient
risk
poorer
respons
impair
respons
system
steroid
certain
subgroup
result
higher
rate
hospit
admiss
andor
impair
recoveri
would
challeng
current
standard
practic
call
immedi
search
better
approach
given
high
preval
suspect
factor
young
age
viral
infect
environment
tobacco
smoke
potenti
impact
poor
respons
rate
